Streetbeat News

Products Services

GH

FDA staff have raised concerns that Guardant Health's test may fail to detect some types of advanced adenomas in patients, according to briefing documents cited by Reuters.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:43 pm

PL

Planet Labs PBC (NYSE:PL) has expanded its commercial partnership with BASF Digital Farming GmbH. BASF Digital Farming will increase its use of Planet's satellite data products to enhance its xarvio® Digital Farming Solutions.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:43 pm

OZEM

Roundhill Investments has launched the Roundhill GLP-1 & Weight Loss ETF (OZEM), which focuses on the growing weight loss management market. The ETF began trading on Nasdaq and targets the GLP-1 receptor agonists and weight management drugs sector.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:42 pm

MYMD

PMCB

PharmaCyte Biotech (NASDAQ: PMCB) has invested $7 million in MyMD Pharmaceuticals (NASDAQ: MYMD), a clinical stage biopharmaceutical company. This investment aligns with PharmaCyte's strategy to utilize its significant cash position to create additional stockholder value. MyMD has reported positive data from a Phase 2 clinical trial for its lead product, MYMD-1, in sarcopenia.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:41 pm

ZM

Zoom Video Communications, Inc. (NASDAQ:ZM) has announced the global availability of post-quantum end-to-end encryption (E2EE) for Zoom Workplace, specifically for Zoom Meetings. This makes Zoom the first UCaaS company to offer such a solution for video conferencing, with plans to extend it to Zoom Phone and Zoom Rooms soon.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:38 pm

AMD

AMD has announced the availability of the AMD EPYC 4004 Series processors, expanding its EPYC server CPU portfolio with cost-optimized offerings aimed at small and medium businesses and hosted IT service providers.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:36 pm

RNXT

RenovoRx (NASDAQ: RNXT) announced the publication of pre-clinical studies that support the efficacy and drug delivery mechanism of its TAMP therapy platform. The studies show that TAMP increases intra-arterial pressure, leading to a 100-fold increase in local tissue concentration of the therapy, potentially improving efficacy, safety, and widening the therapeutic window of drugs. The data was published in the Journal of Vascular Interventional Radiology.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:36 pm

LLY

NVO

Eli Lilly (NYSE:LLY) has received approval from Chinese regulators for its diabetes drug tirzepatide, setting the stage for competition with Novo Nordisk (NYSE:NVO) in the Asian market. This approval could lead to significant market growth for both companies in China.

Portfolio Pulse from Vandana Singh

May 21, 2024 | 1:36 pm

BABA

BYDDY

LI

MCHI

TCOM

Goldman Sachs has raised its forecast for the Chinese market, citing a significant rally in Chinese stocks and a reduction in property-related risks. The MSCI China Index, tracked by the iShares MSCI China ETF (NYSE:MCHI), has seen substantial gains. Goldman Sachs has launched a 40-stock China Recovery Portfolio, including prominent stocks like Alibaba (NYSE:BABA), BYD (OTCPK:BYDDY), Li Auto (NASDAQ:LI), and Trip.com (NASDAQ:TCOM).

Portfolio Pulse from Piero Cingari

May 21, 2024 | 1:32 pm

LEXX

Lexaria has been granted two new patents: Patent #21 for compositions and methods for treating hypertension, and Patent #24 for compositions and methods for treating epilepsy.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:32 pm